Eplerenone for mild systolic CHF

Aldosterone antagonists reduce mortality in patients with severe systolic CHF, but their effects on mild CHF is unknown. This large trial randomized patients with an EF<35% and NYHA stage II symptoms to placebo or eplerenone. After almost 2 years of follow up, significantly fewer patients in the eplerenone group experienced the primary endpoint (CV death or CHF hospitalization) or death. Eplerenone reduces mortality in patients with systolic CHF and mild symptoms (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment